Abstract
Platinum-based complexes, as one of the mainstay chemotherapeutic agents in oncology, have evolved from first-generation Cisplatin to third-generation Oxaliplatin, with numerous platinum complexes currently under clinical investigation. This review systematically evaluates all existing platinum complexes for lung cancer treatment, including three generations of approved agents and investigational candidates, with comprehensive analysis of therapeutic efficacy and toxicity profiles. Our assessment aims to provide novel insights for developing next-generation platinum complexes with optimal therapeutic potential.